Market News AIOpen the app

Recursion Pharmaceuticals is buying into Rallybio's REV102 program, giving Rallybio extra money now and possibly later.

DealRead the original at newsfilter.io
Good for RXRX

Recursion gains an interest in REV102, expanding its drug portfolio. The payment is a cost, but the source reports no setback to its other work, so the added program makes this positive for Recursion.

RXRX · Recursion Pharmaceuticals

AI read · Good for RXRX

The AI's read

A stake in REV102 gives Recursion another drug program in its portfolio. The payment is a real cost, but the source reports no setback to Recursion's other work. The added program makes this positive for Recursion.

RLYB · Rallybio Corporation

AI read · Good for RLYB

The connection

Rallybio transfers an interest in REV102 and receives $7.5 million in upfront equity, with up to $25 million total consideration. The added capital is expected to help Rallybio keep operating through mid-2027, making the deal positive despite giving up an interest in the program.

Get alerts for RXRX

Follow Recursion Pharmaceuticals (RXRX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for RXRX
Free on the App Store and Google Play, or on the web.